Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts


CEO: Gordon Sanghera


Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

Beam the MinIon Up

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

The study demonstrated the efficacy of using the Oxford Nanopore MinIon and a bespoke computational pipeline to perform metagenomics testing of viral infections in patients. 

Using MinIon sequence data, they assembled the genomes of two bacterial isolates after culturing them for two weeks in a chip submerged in a stream.

The goal is to develop a test that can identify the pathogen involved and predict antibiotic susceptibility within six hours of taking a urine sample.

At The Atlantic, Ed Yong reports on the MinION's use to track Ebola in Africa.

In a paper in Nature Nanotechnology, the scientists demonstrate parallel measurements from many nanopores with single-base resolution, though not yet sequencing.

While the MinIon could generate influenza genome data in a clinically relevant timeframe, discrepancies in the sequence suggest it may not yet be ready for diagnostic use.

On its first mission, the MinION will sequence phage lambda, bacterial, and mouse DNA to demonstrate that sequencing in space is feasible.

Including the latest round, the company has raised £251 million in total.

The $75,000 deposit converts into credit for consumables and workflows once participants have accepted the instrument.


A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.